Skip to main content

Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.

Publication ,  Journal Article
Lewis, JP; Ryan, K; O'Connell, JR; Horenstein, RB; Damcott, CM; Gibson, Q; Pollin, TI; Mitchell, BD; Beitelshees, AL; Pakzy, R; Tanner, K ...
Published in: Circ Cardiovasc Genet
April 2013

BACKGROUND- Aspirin or dual antiplatelet therapy with aspirin and clopidogrel is a standard therapy for patients who are at increased risk for cardiovascular events. However, the genetic determinants of variable response to aspirin (alone and in combination with clopidogrel) are not known. METHODS AND RESULTS- We measured ex vivo platelet aggregation before and after dual antiplatelet therapy in individuals (n=565) from the Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and conducted a genome-wide association study of drug response. Significant findings were extended by examining genotype and cardiovascular outcomes in 2 independent aspirin-treated cohorts: 227 percutaneous coronary intervention patients and 1000 patients of the International Verapamil SR/Trandolapril Study (INVEST) Genetic Substudy (INVEST-GENES). Results from the genome-wide association study revealed a strong association between single-nucleotide polymorphisms on chromosome 1q23 and post-dual antiplatelet therapyplatelet aggregation. Further genotyping revealed rs12041331 in the platelet endothelial aggregation receptor-1 (PEAR1) gene to be most strongly associated with dual antiplatelet therapy response (P=7.66×10(-9)). In white and black patients undergoing percutaneous coronary intervention, A-allele carriers of rs12041331 were more likely to experience a cardiovascular event or death compared with GG homozygotes (hazard ratio, 2.62; 95% confidence interval, 0.96-7.10; P=0.059; and hazard ratio, 3.97; 95% confidence interval, 1.10-14.31; P=0.035, respectively). In aspirin-treated INVEST-GENES patients, rs12041331 A-allele carriers had significantly increased risk of myocardial infarction compared with GG homozygotes (odds ratio, 2.03; 95% confidence interval, 1.01-4.09; P=0.048). CONCLUSION- Common genetic variation in PEAR1 may be a determinant of platelet response and cardiovascular events in patients on aspirin alone or in combination with clopidogrel. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00799396 and NCT00370045.

Duke Scholars

Published In

Circ Cardiovasc Genet

DOI

EISSN

1942-3268

Publication Date

April 2013

Volume

6

Issue

2

Start / End Page

184 / 192

Location

United States

Related Subject Headings

  • Ticlopidine
  • Receptors, Cell Surface
  • Polymorphism, Single Nucleotide
  • Platelet Aggregation Inhibitors
  • Platelet Aggregation
  • Odds Ratio
  • Middle Aged
  • Male
  • Humans
  • Genotype
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lewis, J. P., Ryan, K., O’Connell, J. R., Horenstein, R. B., Damcott, C. M., Gibson, Q., … Shuldiner, A. R. (2013). Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet, 6(2), 184–192. https://doi.org/10.1161/CIRCGENETICS.111.964627
Lewis, Joshua P., Kathleen Ryan, Jeffrey R. O’Connell, Richard B. Horenstein, Coleen M. Damcott, Quince Gibson, Toni I. Pollin, et al. “Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.Circ Cardiovasc Genet 6, no. 2 (April 2013): 184–92. https://doi.org/10.1161/CIRCGENETICS.111.964627.
Lewis JP, Ryan K, O’Connell JR, Horenstein RB, Damcott CM, Gibson Q, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013 Apr;6(2):184–92.
Lewis, Joshua P., et al. “Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.Circ Cardiovasc Genet, vol. 6, no. 2, Apr. 2013, pp. 184–92. Pubmed, doi:10.1161/CIRCGENETICS.111.964627.
Lewis JP, Ryan K, O’Connell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshees AL, Pakzy R, Tanner K, Parsa A, Tantry US, Bliden KP, Post WS, Faraday N, Herzog W, Gong Y, Pepine CJ, Johnson JA, Gurbel PA, Shuldiner AR. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013 Apr;6(2):184–192.

Published In

Circ Cardiovasc Genet

DOI

EISSN

1942-3268

Publication Date

April 2013

Volume

6

Issue

2

Start / End Page

184 / 192

Location

United States

Related Subject Headings

  • Ticlopidine
  • Receptors, Cell Surface
  • Polymorphism, Single Nucleotide
  • Platelet Aggregation Inhibitors
  • Platelet Aggregation
  • Odds Ratio
  • Middle Aged
  • Male
  • Humans
  • Genotype